Business
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line. This init
About this update from Jupiter Neurosciences, Inc.
[{"type":"image","alt":"Jupiter Neurosciences, Inc.","displaySize":"","headline":null,"caption":"Jupiter Neurosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pYMq4mt4Y617fyJqYqyXSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6","width":300,"height":89}},"lazy":false},{"type":"text","content":"Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss","length":110,"tagName":"p"},{"type":"text","content":"Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line.","length":379,"tagName":"p"},{"type":"text","content":"This initiative reinforces Jupiter’s dual-engine strategy, combining a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business. As GLP-1 adoption accelerates globally, Jupiter sees an opportunity to serve a growing population seeking science-backed, pharmaceutical-grade solutions that extend beyond weight loss alone.","length":346,"tagName":"p"},{"type":"text","content":"GLP-1 receptor agonists have rapidly transformed the global landscape of obesity and metabolic health by driving meaningful and sustained weight loss. However, increasing clinical and consumer awareness highlights that GLP-1-induced weight loss can place significant physiological demands on mitochondrial energy production, lean tissue preservation, and neuro-gut inflammatory balance. Jupiter believes these biological pressures represent an unmet need as millions of individuals seek solutions that support long-term metabolic resilience and healthspan.","length":556,"tagName":"p"},{"type":"text","content":"“GLP-1 therapies drive weight loss, but biology still must sustain it, the Aesthetic Surgery Journal recently reported that Patients with significant weight loss may look up to 5 years older than peers without s...